[Microbiological evaluation of the effectiveness of gynalgin in the treatment of vaginitis].
The microbiological effectiveness of the preparation Gynalgin produced by POLFA Pharmaceutical Works in Rzeszów was assessed in cases of vulvovaginitis in 55 patients with clinically diagnosed inflammatory conditions of the lower genital tract, who were given Gynalgin tablets in 10-day courses. Vaginal smears were examined three times for the presence of bacteria, fungi and trichomonas vaginalis (before and immediately after the treatment, and two weeks later). In the initial examination in five vaginal smears mixed bacterial flora was found, in 6 smears trichomonas was present, in 4--bacteria and fungi, and in one--trichomonas and fungi. After the treatment in control examinations I and II the number of the isolated bacterial strains was lower, trichomonas was no longer present, and the number of fungi was reduced evidently. In the light of these microbiological examinations Gynalgin was found to exert a strong fungicidal, bactericidal and antitrichomonal activity, and the results of laboratory investigations agreed with those of clinical trials of Gynalgin effectiveness.
Sikorski
R
R
Kliniki Ginekologii Instytutu Połoznictwa i Chorób Kobiecych Ak. Med., Lublinie.
Hencner
Z
Z
Gliński
Z
Z
Wawrzkiewicz
K
K
Radomański
T
T
Milart
P
P
Paszkowski
T
T
Skrzypczak
W
W
Sławiński
P
P
Maruszak
E
E
D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage* / Q000494:pharmacology; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000494:pharmacology; D000994:Antitrichomonal Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000469:parasitology; D002176:Candida albicans / Q000187:drug effects; D002181:Candidiasis, Vulvovaginal / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000469:parasitology; D002750:Chlorquinaldol / Q000008:administration & dosage* / Q000494:pharmacology; D004338:Drug Combinations; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008795:Metronidazole / Q000008:administration & dosage* / Q000494:pharmacology; D014247:Trichomonas Vaginitis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000469:parasitology; D014246:Trichomonas vaginalis / Q000187:drug effects; D014848:Vulvovaginitis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000469:parasitology
D000891:Anti-Infective Agents, Local; D000935:Antifungal Agents; D000994:Antitrichomonal Agents; D004338:Drug Combinations; C078596:Gynalgin; D008795:Metronidazole; D002750:Chlorquinaldol
Ocena mikrobiologiczna skuteczności Gynalginu w zapaleniach pochwy u kobiet.